<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01991223</url>
  </required_header>
  <id_info>
    <org_study_id>CRBD_DEX_PHPKHC</org_study_id>
    <secondary_id>CRBD_SNUH1</secondary_id>
    <nct_id>NCT01991223</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine for Catheter-related Bladder Discomfort</brief_title>
  <acronym>CRBDEX</acronym>
  <official_title>Efficacy of Dexmedetomidine for the Therapy of Catheter-related Bladder Discomfort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of dexmedetomidine for the prevention of catheter-related bladder
      discomfort
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After transurethral bladder resection, large-sized foley catheter have been used for drainage
      of urine and residual blood. Because of urinary catheterization, patients usually experiences
      catheter-related bladder discomfort defined as a burning sensation with an urge to void or
      discomfort in the supra-pubic region caused by catheter- related bladder irritation.

      Dexmedetomidine is an alpha-2 antagonist and used as an analgesic agent. The investigators
      try to evaluate The efficacy of dexmedetomidine for the treatment of catheter-related bladder
      discomfort
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with catheter-related bladder discomfort</measure>
    <time_frame>at postoperative 1 hour</time_frame>
    <description>catheter-related bladder discomfort at postoperative 1 hour was evaluated as none, mild, moderate, severe. The number of patients with mild, moderate, severe discomfort will be calculated and compared between groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catheter-related bladder discomfort</measure>
    <time_frame>at postoperative 0, 1, 6, 24 hours</time_frame>
    <description>Catheter-related bladder discomfort will be evaluated as none, mild, moderate, severe at postoperative 0, 1, 6, 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at suprapubic area</measure>
    <time_frame>at postoperative 0, 1, 6, 24 hours</time_frame>
    <description>Pain at suprapubic area will be evaluated using NRS (0:none, 100:worst imaginable) at postoperative 0, 1, 6, 24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Pain</condition>
  <condition>Blood Pressure</condition>
  <condition>Nausea</condition>
  <condition>Vomiting</condition>
  <condition>Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NS infusion will be done during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DEX infusion will be done during surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dex infusion</intervention_name>
    <description>Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)</description>
    <arm_group_label>Dex group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NS infusion</intervention_name>
    <description>Normal saline will be infused during surgery</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for transurethral bladder resection

          -  ASA I-III

        Exclusion Criteria:

          -  Patient who disagrees to participate this investigation

          -  Patient with severe cardiovascular disease

          -  Patient with small-sized foley catheter (less than 18 Fr.)

          -  Patinets with any urinary tract obstructions

          -  Patient with hyperactive or neurogenic bladder

          -  Patients with chronic renal failure

          -  Patient with morbidly obese

          -  Patients with neurogenic disorder

          -  Patient with medications for chronic pain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hee-Pyoung Park</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University of Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyun-Chang Kim, MD</last_name>
    <email>onidori1979@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hee-Pyong Park, Ph.D</last_name>
    <email>hppark@snu.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee-Pyung Park, MD PhD</last_name>
      <phone>82-2-2072-2365</phone>
      <email>hppark@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Hee-Pyung Park, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyun-Chang Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 18, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Hee-Pyoung Park</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

